Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada.
Identifieur interne : 000066 ( Main/Exploration ); précédent : 000065; suivant : 000067Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada.
Auteurs : David Champredon [Canada] ; Marek Laskowski [Canada] ; Nathalie Charland [Canada] ; Seyed M. Moghadas [Canada]Source :
- Scientific reports [ 2045-2322 ] ; 2018.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Vaccins antigrippaux.
- ressources et distribution : Vaccins antigrippaux.
- épidémiologie : Grippe humaine, Ontario.
- Humains, Pandémies, Programmes de vaccination, Simulation numérique, Vaccination.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- geographic , epidemiology : Ontario.
- epidemiology : Influenza, Human.
- methods : Immunization Programs.
- prevention & control : Pandemics.
- chemical , supply & distribution : Influenza Vaccines.
- Computer Simulation, Humans, Vaccination.
Abstract
New vaccine production technologies can significantly shorten the timelines for availability of a strain-specific vaccine in the event of an influenza pandemic. We sought to evaluate the potential benefits of early vaccination in reducing the clinical attack rate (CAR), taking into account the timing and speed of vaccination roll-out. Various scenarios corresponding to the transmissibility of a pandemic strain and vaccine prioritization strategies were simulated using an agent-based model of disease spread in Ontario, the largest Canadian province. We found that the relative reduction of the CAR reached 60% (90%CI: 44-100%) in a best-case scenario, in which the pandemic strain was moderately transmissible, vaccination started 4 weeks before the first imported case, the vaccine administration rate was 4 times higher than its average for seasonal influenza, and the vaccine efficacy was up to 90%. But the relative reductions in the CAR decreased significantly when the vaccination campaign was delayed or the administration rate reduced. In urban settings with similar characteristics to our population study, early availability and high rates of vaccine administration has the potential to substantially reduce the number of influenza cases. Low rates of vaccine administration or uptake can potentially offset the benefits of early vaccination.
DOI: 10.1038/s41598-018-24764-7
PubMed: 29691450
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada.</title><author><name sortKey="Champredon, David" sort="Champredon, David" uniqKey="Champredon D" first="David" last="Champredon">David Champredon</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario, Canada. david.champredon@gmail.com.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Laskowski, Marek" sort="Laskowski, Marek" uniqKey="Laskowski M" first="Marek" last="Laskowski">Marek Laskowski</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Charland, Nathalie" sort="Charland, Nathalie" uniqKey="Charland N" first="Nathalie" last="Charland">Nathalie Charland</name><affiliation wicri:level="1"><nlm:affiliation>Medicago Inc., 1020 Route de l'Eglise, Quebec, G1V 3V9, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago Inc., 1020 Route de l'Eglise, Quebec, G1V 3V9, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Moghadas, Seyed M" sort="Moghadas, Seyed M" uniqKey="Moghadas S" first="Seyed M" last="Moghadas">Seyed M. Moghadas</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29691450</idno><idno type="pmid">29691450</idno><idno type="doi">10.1038/s41598-018-24764-7</idno><idno type="wicri:Area/Main/Corpus">000048</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000048</idno><idno type="wicri:Area/Main/Curation">000048</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000048</idno><idno type="wicri:Area/Main/Exploration">000048</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada.</title><author><name sortKey="Champredon, David" sort="Champredon, David" uniqKey="Champredon D" first="David" last="Champredon">David Champredon</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario, Canada. david.champredon@gmail.com.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Laskowski, Marek" sort="Laskowski, Marek" uniqKey="Laskowski M" first="Marek" last="Laskowski">Marek Laskowski</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Charland, Nathalie" sort="Charland, Nathalie" uniqKey="Charland N" first="Nathalie" last="Charland">Nathalie Charland</name><affiliation wicri:level="1"><nlm:affiliation>Medicago Inc., 1020 Route de l'Eglise, Quebec, G1V 3V9, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicago Inc., 1020 Route de l'Eglise, Quebec, G1V 3V9, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Moghadas, Seyed M" sort="Moghadas, Seyed M" uniqKey="Moghadas S" first="Seyed M" last="Moghadas">Seyed M. Moghadas</name><affiliation wicri:level="1"><nlm:affiliation>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><series><title level="j">Scientific reports</title><idno type="eISSN">2045-2322</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Computer Simulation</term><term>Humans</term><term>Immunization Programs (methods)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (supply & distribution)</term><term>Influenza, Human (epidemiology)</term><term>Ontario (epidemiology)</term><term>Pandemics (prevention & control)</term><term>Vaccination</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Ontario (épidémiologie)</term><term>Pandémies ()</term><term>Programmes de vaccination ()</term><term>Simulation numérique</term><term>Vaccination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (ressources et distribution)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ontario</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization Programs</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>Ontario</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Computer Simulation</term><term>Humans</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Pandémies</term><term>Programmes de vaccination</term><term>Simulation numérique</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">New vaccine production technologies can significantly shorten the timelines for availability of a strain-specific vaccine in the event of an influenza pandemic. We sought to evaluate the potential benefits of early vaccination in reducing the clinical attack rate (CAR), taking into account the timing and speed of vaccination roll-out. Various scenarios corresponding to the transmissibility of a pandemic strain and vaccine prioritization strategies were simulated using an agent-based model of disease spread in Ontario, the largest Canadian province. We found that the relative reduction of the CAR reached 60% (90%CI: 44-100%) in a best-case scenario, in which the pandemic strain was moderately transmissible, vaccination started 4 weeks before the first imported case, the vaccine administration rate was 4 times higher than its average for seasonal influenza, and the vaccine efficacy was up to 90%. But the relative reductions in the CAR decreased significantly when the vaccination campaign was delayed or the administration rate reduced. In urban settings with similar characteristics to our population study, early availability and high rates of vaccine administration has the potential to substantially reduce the number of influenza cases. Low rates of vaccine administration or uptake can potentially offset the benefits of early vaccination.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29691450</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>04</Month><Day>24</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada.</ArticleTitle><Pagination><MedlinePgn>6492</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-018-24764-7</ELocationID><Abstract><AbstractText>New vaccine production technologies can significantly shorten the timelines for availability of a strain-specific vaccine in the event of an influenza pandemic. We sought to evaluate the potential benefits of early vaccination in reducing the clinical attack rate (CAR), taking into account the timing and speed of vaccination roll-out. Various scenarios corresponding to the transmissibility of a pandemic strain and vaccine prioritization strategies were simulated using an agent-based model of disease spread in Ontario, the largest Canadian province. We found that the relative reduction of the CAR reached 60% (90%CI: 44-100%) in a best-case scenario, in which the pandemic strain was moderately transmissible, vaccination started 4 weeks before the first imported case, the vaccine administration rate was 4 times higher than its average for seasonal influenza, and the vaccine efficacy was up to 90%. But the relative reductions in the CAR decreased significantly when the vaccination campaign was delayed or the administration rate reduced. In urban settings with similar characteristics to our population study, early availability and high rates of vaccine administration has the potential to substantially reduce the number of influenza cases. Low rates of vaccine administration or uptake can potentially offset the benefits of early vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Champredon</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7090-8757</Identifier><AffiliationInfo><Affiliation>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario, Canada. david.champredon@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laskowski</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charland</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medicago Inc., 1020 Route de l'Eglise, Quebec, G1V 3V9, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moghadas</LastName><ForeName>Seyed M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Agent-Based Modelling Laboratory, York University, Toronto, M3J 1P3, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000600" MajorTopicYN="Y">supply & distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29691450</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-24764-7</ArticleId><ArticleId IdType="pii">10.1038/s41598-018-24764-7</ArticleId><ArticleId IdType="pmc">PMC5915538</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 2013 Dec 1;178(11):1655-62</Citation><ArticleIdList><ArticleId IdType="pubmed">24100954</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2013 Jul;57(2):167-75</Citation><ArticleIdList><ArticleId IdType="pubmed">23532475</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2018 Mar 4;14 (3):647-656</Citation><ArticleIdList><ArticleId IdType="pubmed">29252098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2009 Aug;9(8):473-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19628172</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Jul 4;26(29-30):3742-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18524428</ArticleId></ArticleIdList></Reference><Reference><Citation>Math Biosci Eng. 2014 Oct;11(5):1045-63</Citation><ArticleIdList><ArticleId IdType="pubmed">25347806</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2011 Dec 14;11:932</Citation><ArticleIdList><ArticleId IdType="pubmed">22168242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Dec 16;33(51):7160-7167</Citation><ArticleIdList><ArticleId IdType="pubmed">26562321</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 2015 Nov;26(6):862-72</Citation><ArticleIdList><ArticleId IdType="pubmed">26133025</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(8):e23176</Citation><ArticleIdList><ArticleId IdType="pubmed">21858018</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemics. 2012 Aug;4(3):132-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22939310</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Nov 4;302(17 ):1872-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19822627</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2011 Jul 1;174(1):109-17</Citation><ArticleIdList><ArticleId IdType="pubmed">21602300</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Recomm Rep. 2011 Jan 21;60(1):1-24</Citation><ArticleIdList><ArticleId IdType="pubmed">21248682</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 May 2;30(21):3209-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22387221</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2014 Sep 04;14:480</Citation><ArticleIdList><ArticleId IdType="pubmed">25186370</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Nov 19;339:b4571</Citation><ArticleIdList><ArticleId IdType="pubmed">19926697</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Biopharm. 2015 Aug;94:251-63</Citation><ArticleIdList><ArticleId IdType="pubmed">26047796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2012 Feb 7;156(3):173-81</Citation><ArticleIdList><ArticleId IdType="pubmed">22312137</ArticleId></ArticleIdList></Reference><Reference><Citation>J R Soc Interface. 2015 Feb 6;12(103):null</Citation><ArticleIdList><ArticleId IdType="pubmed">25540241</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Sep 8;437(7056):209-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16079797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965</Citation><ArticleIdList><ArticleId IdType="pubmed">24718923</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2017 Apr 11;35(16):1996-2006</Citation><ArticleIdList><ArticleId IdType="pubmed">28302409</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2016 Oct 18;16(1):576</Citation><ArticleIdList><ArticleId IdType="pubmed">27756233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1998 Jul;178(1):53-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9652423</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2015 Dec 14;5:18062</Citation><ArticleIdList><ArticleId IdType="pubmed">26658016</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2015 May 1;60 Suppl 1:S20-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25878298</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Rev. 2013 Jul;26(3):476-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23824369</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2009 May 1;48(9):1254-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19323631</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010 May 06;5(5):e10520</Citation><ArticleIdList><ArticleId IdType="pubmed">20463898</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583</Citation><ArticleIdList><ArticleId IdType="pubmed">29109276</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2007 Jan;4(1):e15</Citation><ArticleIdList><ArticleId IdType="pubmed">17253900</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Res Notes. 2015 May 08;8:191</Citation><ArticleIdList><ArticleId IdType="pubmed">25953076</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Nov 17;438(7066):355-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16292310</ArticleId></ArticleIdList></Reference><Reference><Citation>Math Biosci Eng. 2011 Jan;8(1):113-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21361403</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2010 Mar;4(2):101-12</Citation><ArticleIdList><ArticleId IdType="pubmed">20167050</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 May 15;201(10):1509-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20377412</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Champredon, David" sort="Champredon, David" uniqKey="Champredon D" first="David" last="Champredon">David Champredon</name></noRegion><name sortKey="Charland, Nathalie" sort="Charland, Nathalie" uniqKey="Charland N" first="Nathalie" last="Charland">Nathalie Charland</name><name sortKey="Laskowski, Marek" sort="Laskowski, Marek" uniqKey="Laskowski M" first="Marek" last="Laskowski">Marek Laskowski</name><name sortKey="Moghadas, Seyed M" sort="Moghadas, Seyed M" uniqKey="Moghadas S" first="Seyed M" last="Moghadas">Seyed M. Moghadas</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000066 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000066 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29691450
|texte= Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, Canada.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29691450" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |